AMAALA
9.6.2020 10:02:13 CEST | Business Wire | Press release
AMAALA, the ultra-luxury destination located along Saudi Arabia’s northwestern coast, appointed Saudi Arabian Parsons Limited (Parsons), who, following a competitive tender, was awarded the construction supervision contract. The digitally enabled solutions provider is taking on the role of engineer, supervising the execution of works currently underway across Phase I of Triple Bay.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200609005322/en/
Binyah, a Saudi Real Estate Infrastructure Company, joins Parsons onsite carrying out the excavation, backfilling, and earthworks required to achieve the formation levels and grading of Phase I of the Triple Bay masterplan.
Chief Executive Officer of AMAALA, Nicholas Naples said: "We are delighted to work with two prestigious firms on a project of this scale. We are very pleased with the progress to date and have welcomed the expertise and experience both Parsons and Binyah have brought to the development of the destination. We celebrated a milestone moment in our history when work onsite began, and we are looking forward to working closely together to bring our vision for Triple Bay to life. Together we will deliver an ultra-luxury destination for future generations around the globe, nested in the long-term vision of the Kingdom of Saudi Arabia."
AMAALA’s environmental team is guiding Parsons and Binyah on the AMAALA site to oversee all stages of development, ensuring work is being carried out within its sustainability and environmental guidelines.
Commenting on the signing, Managing Director of Saudi Arabian Parsons Limited, Ken Murray, said: "As an iconic development in the Kingdom, AMAALA is set to become a preeminent destination for travellers from the world over. Parsons is thrilled to join the delivery team, and we look forward to supporting the Triple Bay development and continue our proud participation in the delivery of Vision 2030 for Saudi Arabia."
Chief Executive Officer of Binyah, Eng. Fahad Al-Mesfir stated: "The agreement marked a strategic turning point for the company, given it’s the first business agreement with AMAALA to implement the preparatory works. Binyah is working to provide the highest quality standards in the implementation of the project, which will contribute to achieving the ambitions of the Kingdom’s 2030 vision."
Set in the Prince Mohammed bin Salman Nature Reserve across three unique communities, AMAALA will bring to life the desires and ambitions of a community passionate about shaping and living transformative moments. AMAALA’s trio of communities – Triple Bay, The Coastal Development, and The Island – will showcase three different sets of experiences for guests.
- Triple Bay will offer a fully holistic wellness retreat, state-of-the-art diagnostic medical facilities and authentic treatments designed to feature the local environment. Triple Bay will also be home to a fully integrated sports and entertainment community.
- The Costal Development is set to become the defining hub of contemporary art in the Middle East, playing host to a dynamic programme of exciting events from the global arts and cultural calendar.
- The Island will be the tranquil home of an exclusive art community, and an Arabic botanical garden bestrewn with sculptural pieces.
With a focus on creating transformative personal journeys inspired by arts, wellness and the purity of the Red Sea, AMAALA will allow travellers to immerse themselves in the finest wellness, arts, culture, sports and fitness offerings, redefining the luxury tourism experience.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005322/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom